O	0	11	Comparative
O	12	20	efficacy
O	21	23	of
B-intervention	24	35	palbociclib
I-intervention	35	36	,
I-intervention	37	47	ribociclib
I-intervention	48	51	and
I-intervention	52	63	abemaciclib
O	64	67	for
O	68	70	ER
O	70	71	+
O	72	82	metastatic
O	83	89	breast
O	90	96	cancer
O	96	97	:
O	98	100	an
O	101	109	adjusted
O	110	118	indirect
O	119	127	analysis
O	128	130	of
O	131	141	randomized
O	142	152	controlled
O	153	159	trials
O	159	160	.

O	161	168	Several
O	169	175	trials
O	176	180	have
O	181	193	demonstrated
O	194	197	the
O	198	205	benefit
O	206	208	of
O	209	213	anti
O	213	214	-
O	214	218	CDK4
O	218	219	/
O	219	220	6
O	221	231	inhibitors
O	232	236	plus
O	237	246	endocrine
O	247	254	therapy
O	255	257	in
O	258	266	estrogen
O	267	275	receptor
O	275	276	-
O	276	284	positive
O	285	286	(
O	286	288	ER
O	288	289	+
O	289	290	)
O	291	299	advanced
O	300	306	breast
O	307	313	cancer
O	314	315	(
O	315	317	BC
O	317	318	)
O	318	319	,
O	320	322	in
O	323	328	first
O	329	331	or
O	332	342	subsequent
O	343	348	lines
O	349	351	of
O	352	359	therapy
O	359	360	.

O	361	368	However
O	368	369	,
O	370	373	due
O	374	376	to
O	377	380	the
O	381	385	lack
O	386	388	of
O	389	395	direct
O	395	396	/
O	396	404	indirect
O	405	416	comparisons
O	416	417	,
O	418	423	there
O	424	427	are
O	428	430	no
O	431	435	data
O	436	449	demonstrating
O	450	453	the
O	454	465	superiority
O	466	468	of
O	469	472	one
O	473	477	drug
O	478	482	over
O	483	486	the
O	487	492	other
O	492	493	.

O	494	496	We
O	497	505	compared
O	506	509	the
O	510	523	effectiveness
O	524	526	of
O	527	538	palbociclib
O	538	539	,
O	540	550	ribociclib
O	550	551	,
O	552	555	and
O	556	567	abemaciclib
O	568	570	in
B-eligibility	571	579	advanced
I-eligibility	580	582	ER
I-eligibility	583	584	+
I-eligibility	585	587	BC
O	588	591	via
O	592	594	an
O	595	603	indirect
O	604	612	adjusted
O	613	621	analysis
O	621	622	.

O	623	625	We
O	626	635	performed
O	636	646	electronic
O	647	655	searches
O	656	658	in
O	659	662	the
O	663	669	PubMed
O	669	670	,
O	671	677	EMBASE
O	677	678	,
O	679	682	and
O	683	691	Cochrane
O	692	701	databases
O	702	705	for
O	706	717	prospective
O	718	723	phase
O	724	725	3
O	726	736	randomized
O	737	743	trials
O	744	754	evaluating
O	755	759	anti
O	759	760	-
O	760	764	CDK4
O	764	765	/
O	765	766	6
O	767	777	inhibitors
O	778	782	plus
O	783	792	endocrine
O	793	799	agents
O	799	800	.

O	801	803	We
O	804	812	compared
O	813	816	the
O	817	824	results
O	825	829	with
O	830	832	an
O	833	841	adjusted
O	842	850	indirect
O	851	859	analysis
O	860	862	of
O	863	873	randomized
O	873	874	-
O	874	884	controlled
O	885	891	trials
O	891	892	.

O	893	901	Outcomes
O	902	904	of
O	905	913	interest
O	914	918	were
B-outcome-Measure	919	930	progression
I-outcome-Measure	930	931	-
I-outcome-Measure	931	935	free
I-outcome-Measure	936	944	survival
I-outcome-Measure	945	946	(
I-outcome-Measure	946	949	PFS
I-outcome-Measure	949	950	)
O	950	951	,
B-outcome-Measure	952	959	overall
I-outcome-Measure	960	968	response
I-outcome-Measure	969	973	rate
I-outcome-Measure	974	975	(
I-outcome-Measure	975	978	ORR
I-outcome-Measure	978	979	)
O	980	983	and
B-outcome-Measure	984	986	G3
I-outcome-Measure	986	987	-
I-outcome-Measure	987	988	4
I-outcome-Measure	989	999	toxicities
O	1000	1009	occurring
O	1010	1012	in
O	1013	1014	â‰¥
O	1015	1016	5
O	1016	1017	%
O	1018	1020	of
O	1021	1029	patients
O	1029	1030	.

O	1031	1034	Six
O	1035	1041	trials
O	1042	1045	and
O	1046	1049	six
O	1050	1059	treatment
O	1060	1064	arms
O	1065	1074	including
O	1075	1076	a
O	1077	1082	total
O	1083	1085	of
B-total-participants	1086	1090	3743
O	1091	1103	participants
O	1103	1104	,
O	1105	1109	were
O	1110	1118	included
O	1118	1119	.

O	1120	1123	For
B-outcome	1124	1127	PFS
O	1128	1131	and
B-outcome	1132	1135	ORR
O	1136	1144	analysis
O	1144	1145	,
O	1146	1149	the
O	1150	1155	three
O	1156	1162	agents
O	1163	1167	were
O	1168	1175	similar
O	1176	1178	in
O	1179	1183	both
O	1184	1189	first
O	1189	1190	-
O	1191	1194	and
O	1195	1201	second
O	1201	1202	-
O	1202	1206	line
O	1207	1214	studies
O	1214	1215	.

O	1216	1219	All
B-outcome	1220	1222	G3
I-outcome	1222	1223	-
I-outcome	1223	1224	4
I-outcome	1225	1235	toxicities
O	1236	1240	were
O	1241	1248	similar
O	1248	1249	,
O	1250	1254	with
O	1255	1262	reduced
O	1263	1267	risk
O	1268	1270	of
B-outcome	1271	1279	diarrhea
O	1280	1283	for
O	1284	1295	palbociclib
O	1296	1302	versus
O	1303	1314	abemaciclib
O	1315	1316	(
O	1316	1324	relative
O	1325	1329	risk
O	1330	1331	[
O	1331	1333	RR
O	1333	1334	]
O	1335	1336	0
O	1336	1337	.
O	1337	1339	13
O	1339	1340	,
O	1341	1343	95
O	1343	1344	%
O	1345	1347	CI
O	1348	1349	0
O	1349	1350	.
O	1350	1352	02
O	1352	1353	-
O	1353	1354	0
O	1354	1355	.
O	1355	1357	92
O	1357	1358	;
O	1359	1360	P
O	1361	1362	=
O	1363	1364	0
O	1364	1365	.
O	1365	1367	04
O	1367	1368	)
O	1369	1372	and
O	1373	1375	of
O	1376	1379	QTc
O	1380	1392	prolongation
O	1393	1396	for
O	1397	1408	palbociclib
O	1409	1415	versus
O	1416	1426	ribociclib
O	1427	1428	(
O	1428	1430	RR
O	1431	1432	0
O	1432	1433	.
O	1433	1435	02
O	1435	1436	,
O	1437	1439	95
O	1439	1440	%
O	1441	1443	CI
O	1444	1445	0
O	1445	1446	-
O	1446	1447	0
O	1447	1448	.
O	1448	1450	83
O	1450	1451	;
O	1452	1453	P
O	1454	1455	=
O	1456	1457	0
O	1457	1458	.
O	1458	1460	03
O	1460	1461	)
O	1461	1462	.

O	1463	1470	Despite
O	1471	1480	different
O	1481	1490	inclusion
O	1491	1499	criteria
O	1500	1503	and
O	1504	1510	length
O	1511	1513	of
O	1514	1520	follow
O	1520	1521	-
O	1521	1523	up
O	1523	1524	,
O	1525	1532	similar
O	1533	1541	features
O	1542	1546	were
O	1547	1554	noticed
O	1555	1560	among
O	1561	1567	second
O	1567	1568	-
O	1568	1572	line
O	1573	1580	studies
O	1581	1585	with
O	1586	1589	the
O	1590	1599	exception
O	1600	1602	of
O	1603	1612	increased
B-outcome	1613	1617	risk
I-outcome	1618	1620	of
I-outcome	1621	1627	anemia
I-outcome	1628	1630	G3
I-outcome	1630	1631	-
I-outcome	1631	1632	4
O	1633	1636	and
B-outcome	1637	1645	diarrhea
I-outcome	1646	1648	G3
I-outcome	1648	1649	-
I-outcome	1649	1650	4
O	1651	1654	for
O	1655	1666	abemaciclib
O	1666	1667	.

O	1668	1673	Based
O	1674	1676	on
O	1677	1680	PFS
O	1681	1684	and
O	1685	1688	ORR
O	1689	1696	results
O	1697	1699	of
O	1700	1704	this
O	1705	1713	indirect
O	1714	1718	meta
O	1718	1719	-
O	1719	1727	analysis
O	1727	1728	,
O	1729	1740	palbociclib
O	1740	1741	,
O	1742	1752	ribociclib
O	1752	1753	,
O	1754	1757	and
O	1758	1769	abemaciclib
O	1770	1773	are
O	1774	1781	equally
O	1782	1791	effective
O	1792	1794	in
O	1795	1801	either
O	1802	1807	first
O	1807	1808	-
O	1809	1811	or
O	1812	1818	second
O	1818	1819	-
O	1819	1823	line
O	1824	1831	therapy
O	1832	1835	for
O	1836	1844	advanced
O	1845	1847	ER
O	1848	1849	+
O	1850	1852	BC
O	1852	1853	.

O	1854	1858	They
O	1858	1859	,
O	1860	1867	however
O	1867	1868	,
O	1869	1875	ported
O	1876	1885	different
O	1886	1894	toxicity
O	1895	1903	profiles
O	1903	1904	.
